论文部分内容阅读
临床设计分为3组:SFDM组64例,NDM组80例及健康对照组32例。治疗前做OGTT、胰岛素及C-肽释放试验作为基线对照,甘精胰岛联合治疗使糖化血红蛋白(HbAlc)水平<7.0%。SFDM组NDM组患者治疗后C-肽释放峰曲线下面积较治疗前明显扩大(P<0.05)。胰岛素、C-肽释放峰值回归正常时相的比例明显升高(,P<0.05或0.01)。NDM组比例明显多于SFDM组(P<0.01)。结论早期联合治疗明显有助于NDM、SFDM患者胰岛功能的恢复,初发NDM获益更多。
The clinical design was divided into 3 groups: 64 cases in SFDM group, 80 cases in NDM group and 32 cases in healthy control group. Before treatment, OGTT, insulin, and C-peptide release were used as baseline controls. Glargardin combined treatment resulted in HbAlc levels <7.0%. The area under the curve of C-peptide release peak in patients with NDM in SFDM group was significantly larger than that before treatment (P <0.05). The peak of insulin and C-peptide release returned to normal phase significantly (P <0.05 or 0.01). The proportion of NDM group was significantly higher than that of SFDM group (P <0.01). Conclusion Early combination therapy can significantly help the recovery of islet function in patients with NDM and SFDM, and the benefit of initial NDM is more.